- ISIN
- US44842L1035
- CUSIP
- 44842L103
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Mar 17, 2016
Highlights
- Market Cap
- $1.94B
- Enterprise Value
- $1.99B
- Total Revenue (TTM)
- $602.20M
- Gross Profit (TTM)
- $53.76M
- EBITDA (TTM)
- -$7.49M
- Year Range
- $9.77 - $18.30
- Target Price
- $17.50
- ROA (TTM)
- 26.63%
- ROE (TTM)
- 37.71%
- Avg. Volume (1M)
- 50K
- Avg. Volume Value (1M)
- $557.29K
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
HCM Performance Chart
HUTCHMED (China) Limited (HCM) is down 16.5% since the beginning of the year. At $11 per share, HCM is trading 39.2% below its 52-week high of $18. Investors who bought $1,000 worth of HCM shares 5 years ago would now be looking at an investment worth $265.
Loading charts...
Compare this symbol against anything
Returns By Period
HUTCHMED (China) Limited (HCM) has returned -16.50% so far this year and -35.55% over the past 12 months. Over the last ten years, HCM has returned -1.61% per year, falling short of the S&P 500 Index benchmark, which averaged 13.26% annually.
HUTCHMED (China) Limited
- 1D
- 3.34%
- 1M
- -2.71%
- 6M
- -25.80%
- YTD
- -16.50%
- 1Y
- -35.55%
- 3Y*
- -9.83%
- 5Y*
- -23.34%
- 10Y*
- -1.61%
- ALL TIME*
- -1.84%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
HCM Monthly Returns History
Based on dividend-adjusted daily data since Mar 17, 2016, HCM's average daily return is +0.06%, while the average monthly return is +0.88%. At this rate, an investment would double in approximately 6.6 years.
Historically, 48% of months were positive and 52% were negative. The best month was Mar 2017 with a return of +56.6%, while the worst month was Dec 2018 at -33.0%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 4 months.
On a daily basis, HCM closed higher 50% of trading days. The best single day was Mar 15, 2017 with a return of +28.4%, while the worst single day was Jun 28, 2019 at -27.2%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 12.53% | -4.47% | 4.40% | -10.16% | -14.81% | -6.03% | 3.44% | -16.50% | |||||
| 2025 | -6.18% | 21.75% | -8.63% | -1.26% | -6.46% | 8.35% | 18.14% | -15.58% | 4.93% | -6.79% | -1.77% | -7.56% | -7.49% |
| 2024 | -30.98% | 20.88% | 11.18% | 10.18% | 0.11% | -7.61% | 13.55% | -10.24% | 11.92% | -7.83% | -5.83% | -14.99% | -20.43% |
| 2023 | 21.92% | -8.16% | -21.33% | 17.05% | -21.26% | 0.00% | 17.25% | 6.75% | 12.78% | 14.99% | -1.03% | -6.07% | 22.53% |
| 2022 | -22.35% | 0.04% | -30.57% | -20.24% | -30.28% | 20.15% | 3.40% | -1.61% | -31.10% | -0.23% | 37.22% | 21.85% | -57.87% |
| 2021 | -0.34% | -9.93% | -1.70% | 0.14% | 5.16% | 32.00% | 7.08% | -4.02% | -9.29% | -19.64% | 15.09% | 3.60% | 9.56% |
Benchmark Metrics
HUTCHMED (China) Limited has an annualized alpha of 1.23%, beta of 1.00, and R2 of 0.09 versus S&P 500 Index. Calculated based on daily prices since March 17, 2016.
- This stock participated in 78.29% of S&P 500 Index downside but only 28.71% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.09 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 1.23%
- Beta
- 1.00
- R²
- 0.09
- Upside Capture
- 28.71%
- Downside Capture
- 78.29%
Return for Risk
Risk / Return Rank
HCM ranks 7 for risk / return — above 7% of stocks peers on PortfoliosLab. Its historical combined result is below most peers; review the five component ranks for context.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for HUTCHMED (China) Limited (HCM) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| HCM | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.43 | ||
| Sortino ratioReturn per unit of downside risk | -3.45 | ||
| Omega ratioGain probability vs. loss probability | 0.83 | 1.25 | -0.43 |
| Calmar ratioReturn relative to maximum drawdown | -0.84 | 2.00 | -2.85 |
| Martin ratioReturn relative to average drawdown | -1.56 | 8.49 | -10.06 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the HUTCHMED (China) Limited. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the HUTCHMED (China) Limited was 82.18%, occurring on Oct 25, 2022. The portfolio has not yet recovered.
The current HUTCHMED (China) Limited drawdown is 74.08%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-82.18%Oct 2022 | 1y 2mo | — | 4y 11moAug 2021 - now | Bear market2022 |
-63.07%Mar 2020 | 2y 2mo | 1y 4mo | 3y 6moJan 2018 - Jul 2021 | COVID crash2020 |
-20.59%Oct 2016 | 3mo 28d | 1mo 21d | 5mo 19dJun 2016 - Dec 2016 | — |
-14.78%Feb 2017 | 1mo 25d | 13d | 2mo 8dJan 2017 - Mar 2017 | — |
-14.57%Dec 2017 | 25d | 10d | 1mo 5dNov 2017 - Dec 2017 | — |
Drawdown Indicators
| HCM | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -82.18% | -56.78% | -25.40% |
Max Drawdown (1Y)Largest decline over 1 year | -44.50% | -9.10% | -35.40% |
Max Drawdown (3Y)Largest decline over 3 years | -54.13% | -18.90% | -35.23% |
Max Drawdown (5Y)Largest decline over 5 years | -82.18% | -25.43% | -56.75% |
Max Drawdown (10Y)Largest decline over 10 years | -82.18% | -33.92% | -48.26% |
Current DrawdownCurrent decline from peak | -74.08% | -1.58% | -72.50% |
Average DrawdownAverage peak-to-trough decline | -40.66% | -10.70% | -29.96% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 23.95% | 2.14% | +21.81% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of HUTCHMED (China) Limited over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how HUTCHMED (China) Limited is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with HCM
Add HUTCHMED (China) Limited to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with HCM